CONSTITUENT REPORT
Menthol
Menthol is the cooling monoterpene alcohol most strongly associated with peppermint and cornmint oils, and it is one of the better documented aroma constituents in this archive. The strongest evidence base covers identity, repeated occurrence in mint oils, TRPM8-mediated cooling pharmacology, and established external-use drug and flavoring frameworks. Human data exist for topical use in symptom-style settings such as migraine and pain relief, but those findings should still be framed as limited use-context evidence rather than broad medical claims.
Chemical identity and composition
PubChem identifies menthol as C10H20O, and the archive context is dominated by naturally occurring L-menthol in peppermint and cornmint materials. The literature often distinguishes racemic menthol from the naturally dominant levorotatory form, so aliases are preserved here for search continuity.
Aroma and practical use
- Use the recorded minty, cooling, fresh, camphoraceous descriptors to explore a blend's scent character; perceived strength also depends on the other ingredients.
- Compare the recorded goal signals with the intended purpose, while keeping model assumptions separate from observed study outcomes.
- Review the flagged use concerns across every contributing oil and the selected dilution.
- Read the route, preparation and experimental context before using a study finding to choose an oil.
Reported benefits and effects
Findings retain their study context. An animal or laboratory result describes that experiment.
topical migraine use context
A controlled migraine study reported a significantly higher number of participants achieving at least one pain-free or pain-relief response after topical 10% menthol than after placebo, with no significant difference in adverse effects between groups.
Measured: pain-free or pain-relief response after cutaneous 10% menthol solution
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
topical pain analgesic context
A 2018 review concluded that menthol's topical pain-relief context is best explained by TRPM8 activation, counterirritant cooling, nociceptor desensitization, and possible central analgesic pathway activation.
Measured: mechanistic and clinical evidence for topical pain applications
Apply this finding only to the studied preparation, participants, route and outcome. It does not establish the same result for a custom oil blend.
anti inflammatory monocyte assay
A human monocyte paper reported that L-menthol significantly suppressed three measured inflammatory mediators in vitro, supporting a preclinical anti-inflammatory signal at the isolated-constituent level.
Measured: IL-1beta, leukotriene B4, and prostaglandin E2 production
This experimental finding does not establish benefit, dose or safety in people using this blend.
How it contributes to goal calculations
Model markers guide the formulation score. They are separate from the source findings above.
Use concerns and concentration limits
Sensitization concernFlagged
Flagged in the constituent reference; assess the source, route and finished-product concentration.
Phototoxicity concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Oxidation concernNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
Penetration enhancementNot flagged
Not flagged in the current model. This is not proof of absence or unrestricted safety.
A recorded constituent reference, not a recommended oil dilution. Product category, source applicability and all contributing oils must be checked before use.
unverified reference · No source provenance attachedThe U.S. FDA OTC external analgesic monograph lists menthol at 0.1-1% as an analgesic/anesthetic active ingredient and 1.25-16% as a cooling counterirritant active ingredient in qualifying topical drug products.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
DailyMed-style warning language for menthol topical products commonly includes avoiding eyes, damaged skin, occlusion with heating pads, and urgent help if swallowed; these are product-use warnings rather than a full constituent toxicology dossier.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Peppermint-oil safety literature and product labeling have also long carried special caution around use near the face of infants and young children because strong menthol exposure may adversely affect breathing.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
No direct public citation is attached to this entry.
Constituents it may interact with
These are research candidates recorded in the interaction matrix. They do not add a proven-amplification bonus to the score.
EugenolAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
in vitro · effect
No source citation attached.
Read Eugenol report →1,8-cineoleAmplification candidate
Candidate in the research matrix. A coefficient alone does not establish amplification at the dose, route or goal of your blend; no proven amplification is inferred from this row.
clinical · whole_oil
No source citation attached.
Read 1,8-cineole report →How the effects were investigated
trpm8 activation and counterirritant cooling
A menthol pharmacology review describes menthol as a selective activator of TRPM8 channels and a vasoactive topical counterirritant that first stimulates then desensitizes nociceptive pathways.
This reference does not establish a therapeutic result or a safe use level for a custom oil blend.
suppression of monocyte inflammatory mediators
An in vitro monocyte study reported that L-menthol significantly suppressed IL-1beta, leukotriene B4, and prostaglandin E2 production compared with control conditions.
This experimental finding does not establish benefit, dose or safety in people using this blend.
What this report cannot establish
- A reported constituent percentage does not establish an effective human therapeutic dose or the amount absorbed into the body.
- The presence of a constituent does not guarantee a clinical benefit, rash treatment or sleep improvement from a custom blend.
- An unflagged concern or missing use limit does not establish safety for ingestion, inhalation, skin exposure or a particular person.
- A candidate constituent interaction does not establish that two oils amplify one another at the selected proportions.
- Constituent descriptors alone do not establish a precise top, heart or base lifetime in a finished blend.
Known data gaps (5)
- The human literature is strongest for topical product contexts and symptom-style endpoints, not for broad standalone therapeutic claims about isolated menthol.
- This pass did not verify a single modern constituent-specific fragrance-safety assessment for menthol comparable to the archive's RIFM-backed records for some other materials.
- The numeric dermal reference lacks source provenance; a verified flag alone is insufficient.
- Some findings do not record an explicit exposure route; consult the linked study before applying them to a use.
- Interaction candidates lack an attached source citation and remain unqualified.